• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Apatinib for EGFR-TKI and chemotherapy refractory in an advanced lung cancer patient: a case report.阿帕替尼用于一名晚期肺癌患者的表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）和化疗难治性病例报告
J Thorac Dis. 2018 Jul;10(7):E564-E569. doi: 10.21037/jtd.2018.06.136.
2
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.阿帕替尼增强了表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）对具有EGFR-TKI耐药性的非小细胞肺癌的抗肿瘤活性。
Eur J Cancer. 2017 Oct;84:184-192. doi: 10.1016/j.ejca.2017.07.037. Epub 2017 Aug 17.
3
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).ACTIVE 研究方案：阿帕替尼或安慰剂联合吉非替尼作为表皮生长因子受体突变型晚期非小细胞肺癌（CTONG1706）患者的一线治疗。
Cancer Commun (Lond). 2019 Nov 7;39(1):69. doi: 10.1186/s40880-019-0414-4.
4
Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report.阿帕替尼用于治疗一名表皮生长因子受体（EGFR）状态未知的晚期非小细胞肺癌患者的EGFR酪氨酸激酶抑制剂（TKI）耐药：一例病例报告
Onco Targets Ther. 2017 Apr 26;10:2289-2295. doi: 10.2147/OTT.S130990. eCollection 2017.
5
Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.阿帕替尼联合化疗治疗晚期上皮性卵巢癌：一例病例报告
Onco Targets Ther. 2017 Mar 13;10:1521-1525. doi: 10.2147/OTT.S126471. eCollection 2017.
6
Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma.阿帕替尼三线治疗肺鳞状细胞癌的长期无进展生存
Onco Targets Ther. 2018 Jul 16;11:4047-4050. doi: 10.2147/OTT.S154567. eCollection 2018.
7
Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma.低剂量阿帕替尼在晚期肺腺癌一线治疗后的疗效
Oncotarget. 2017 Aug 3;8(39):66248-66253. doi: 10.18632/oncotarget.19908. eCollection 2017 Sep 12.
8
Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review.阿帕替尼用于多线治疗后的非小细胞肺癌患者：病例系列报告及文献综述
Saudi J Biol Sci. 2018 Jul;25(5):888-894. doi: 10.1016/j.sjbs.2017.12.011. Epub 2017 Dec 27.
9
Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.阿帕替尼治疗标准多模式治疗失败的晚期骨肉瘤：一项开放标签的 II 期临床试验。
Oncologist. 2019 Jul;24(7):e542-e550. doi: 10.1634/theoncologist.2018-0542. Epub 2018 Dec 17.
10
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].挽救性化疗对化疗及表皮生长因子受体酪氨酸激酶抑制剂治疗失败的晚期非小细胞肺癌患者的疗效
Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63.

引用本文的文献

1
A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy.一项单臂前瞻性研究，评估甲磺酸阿帕替尼联合培美曲塞用于既往化疗失败的晚期非鳞非小细胞肺癌患者。
Ann Transl Med. 2022 Jan;10(2):101. doi: 10.21037/atm-22-79.

本文引用的文献

1
Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.晚期或复发性表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者在影像学进展后继续使用EGFR酪氨酸激酶抑制剂（TKI）：一项观察性研究
ESMO Open. 2017 Sep 14;2(4):e000214. doi: 10.1136/esmoopen-2017-000214. eCollection 2017.
2
Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.肺腺癌中罕见的表皮生长因子受体突变 S768I 对酪氨酸激酶抑制剂的反应：回顾性分析和文献复习。
Target Oncol. 2017 Feb;12(1):81-88. doi: 10.1007/s11523-016-0455-4.
3
Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.阿帕替尼通过抑制RET/Src信号通路，作用于融合激酶KIF5B-RET，从而抑制细胞侵袭和迁移。
Oncotarget. 2016 Sep 13;7(37):59236-59244. doi: 10.18632/oncotarget.10985.
4
Antiangiogenic therapy in oncology: current status and future directions.肿瘤学中的抗血管生成治疗：现状与未来方向。
Lancet. 2016 Jul 30;388(10043):518-29. doi: 10.1016/S0140-6736(15)01088-0. Epub 2016 Feb 5.
5
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.索拉非尼单药治疗非小细胞肺癌（MISSION）试验：一项索拉非尼治疗 2 或 3 种先前治疗方案后复发或难治性主要非鳞状非小细胞肺癌患者的 III 期、多中心、安慰剂对照试验。
J Thorac Oncol. 2015 Dec;10(12):1745-53. doi: 10.1097/JTO.0000000000000693.
6
National estimates of cancer prevalence in China, 2011.中国 2011 年癌症流行情况的全国估计数。
Cancer Lett. 2016 Jan 1;370(1):33-8. doi: 10.1016/j.canlet.2015.10.003. Epub 2015 Oct 13.
7
Clinical advances in the development of novel VEGFR2 inhibitors.新型 VEGFR2 抑制剂研发的临床进展。
Ann Transl Med. 2014 Dec;2(12):123. doi: 10.3978/j.issn.2305-5839.2014.08.14.
8
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy.一项针对晚期非小细胞肺癌非鳞状组织学患者的单臂II期试验，这些患者在含贝伐单抗的治疗中出现疾病进展。
Lung Cancer. 2014 Nov;86(2):288-90. doi: 10.1016/j.lungcan.2014.08.011. Epub 2014 Aug 26.
9
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).多中心 II 期研究：索拉非尼单药治疗 EGFR-TKI 治疗失败的晚期肺腺癌患者（中国胸部肿瘤研究协作组，CTONG 0805）。
Lung Cancer. 2014 Mar;83(3):369-73. doi: 10.1016/j.lungcan.2013.12.014. Epub 2014 Jan 5.
10
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.癌症治疗中的血管生成抑制剂：分类及治疗原理的机制视角
Br J Pharmacol. 2013 Oct;170(4):712-29. doi: 10.1111/bph.12344.

Apatinib for EGFR-TKI and chemotherapy refractory in an advanced lung cancer patient: a case report.

作者信息

Chen Ying, Gong Junping, Zhou Huiming, Qu Xiujuan, Teng Yuee, Liu Yunpeng, Jin Bo

机构信息

Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.

Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China.

出版信息

J Thorac Dis. 2018 Jul;10(7):E564-E569. doi: 10.21037/jtd.2018.06.136.

DOI:10.21037/jtd.2018.06.136
PMID:30174935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6106002/
Abstract
摘要